Pre-Registration Now Open for Occuity’s Republic (Formerly Seedrs) Investment Round

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.  Take 2 mins to learn more.

We are delighted to announce that pre-registration is now open for the next phase of our investment round, hosted on Republic (formerly Seedrs).

This stage gives the opportunity for new and existing crowdfunding investors to join us on our journey as we enter our most exciting phase yet.

Pre-Register Now

Five Reasons to Invest in Occuity

At Occuity, we are developing an innovative optical technology that has the potential to transform how diseases such as glaucoma, myopia, diabetes and Alzheimer’s are detected and monitored.Here are five reasons why we believe now is the perfect time to invest.

1. We have a mission you can believe in - to improve people's lives...

   We use the eye as a window to the health of the body. Our goal is to replace painful, invasive tests with a simple, pain-free optical scan that provides immediate insight into health and disease.

   
   

2. We have built a powerful, patented platform...

   At the heart of Occuity is our optical technology platform, protected by 15 patents (14 Granted, 1 Pending) and supported by over £4 million in grant funding. This proven foundation allows us to create handheld, non-contact medical devices that can scale across multiple markets.

   
   

3. We have the team to deliver our mission....

   Occuity is led by an experienced leadership team with multiple successful exits and decades of experience in optics, engineering and medical device design. Alongside them is a talented group of award-winning scientists, engineers and designers committed to improving lives through innovation.

   
   

4. We are revenue generating, with a significant growth event ahead...

   Our first product, the PM1 Pachymeter, is CE marked and generating sales through a growing international distributor network. The AX1 Axiometer, launching in 2026, targets the fast-growing myopia management market, expected to affect half the world’s population by 2050.

   
   

5. We are not a one-product company...

   Each device builds on our proven platform, strengthening our technology and taking us closer to our ultimate goal — the Indigo, a non-invasive glucose meter for diabetes. This pipeline gives Occuity scalability, defensibility and long-term value creation.

Recent Highlights

Our momentum continues to build, with major recognition over the past few weeks:

• Royal Academy of Engineering Award – The PM1 Pachymeter received the prestigious 2025 Colin Campbell Mitchell Award, recognising the excellence of our engineering and technology platform.

• UK Government Trade Mission to India – Representing UK MedTech innovation abroad, we met with senior government officials including Jason Stockwood, Minister of State for Investment, and Peter Kyle, Secretary of State for Business and Trade.

• Ophthalmology Futures Forum – The AX1 Axiometer was showcased alongside the world’s leading innovations in myopia management, attracting strong interest from industry and potential partners.

  
  

Why Invest Now

With a growing portfolio of products, an award-winning technology platform, and rising international recognition, Occuity is entering a period of accelerated growth.Funds raised through Republic will support the commercial launch of the AX1, expansion of PM1 production, and continued development of our diabetes-focused devices, the SD1 and Indigo.

Occuity is no longer an early-stage concept. We are a validated, growth-stage MedTech company with patented technology, revenue-generating products and a clear roadmap to global scale.

We are building something special, and we are only just getting started.

Pre-register now on Republic (formerly Seedrs) to gain early access when the campaign goes live and join us as we continue to unlock the power of the eye to transform health.

Pre-Register Now